New Faculty 22 Stanley Adoro, Ph.D. Stanley Adoro, Ph.D., has joined the Experimental Immunology Branch as a Stadtman Tenure-Track Investigator from Case Western Reserve University. Dr. Adoro is an immunologist with an interest in understanding the process of blood cell development. Mirit I. Aladjem, Ph.D. Mirit I. Aladjem, Ph.D., has been appointed Deputy Branch Chief of the Developmental Therapeutics Branch. Dr. Aladjem studies cellular signaling pathways that regulate DNA synthesis to help understand cancer biology and elucidate the cellular response to chemotherapeutic drugs. Clint T. Allen, M.D. Clint T. Allen, M.D., has joined the Surgical Oncology Program as a Senior Investigator from the National Institute on Deafness and Other Communication Disorders. Dr. Allen’s research centers on immunologic aspects of head and neck cancer and neoplasm development, progression and treatment. Dr. Allen leads a program that focuses on developing novel treatment approaches for human papillomavirus (HPV)-positive and -negative head and neck squamous cell carcinoma as well as recurrent respiratory papillomatosis (RRP). A. Rouf Banday, Ph.D. A. Rouf Banday, Ph.D., has joined the Genitourinary Malignancies Branch as a Stadtman Tenure-Track Investigator from the NCI Division of Cancer Epidemiology and Genetics. Dr. Banday’s research goal is to understand the genomic alterations that govern the development of bladder cancer and confer resistance to therapies. Lisa D. Boxer, Ph.D. Lisa D. Boxer, Ph.D., has joined the Laboratory of Genome Integrity as a Stadtman Tenure-Track Investigator from Harvard University. Dr. Boxer’s lab studies the role of chromatin regulation in neural development and how mutations in chromatin regulators lead to neurodevelopmental disorders and cancer. John Brognard, Ph.D. John Brognard, Ph.D., has been awarded tenure at NIH and appointed as a Senior Investigator in the Laboratory of Cell and Developmental Signaling. Dr. Brognard’s lab studies cancer-associated kinases using bioinformatics and functional genomic approaches to understand the molecular mechanisms by which these kinases promote tumorigenesis. 23 Takeo Fujii, M.D., M.P.H. Takeo Fujii, M.D., M.P.H., has joined the Women’s Malignancies Branch as a Physician-Scientist Early Investigator from Cold Spring Harbor Laboratory. Dr. Fujii is a medical oncologist whose research focuses on finding novel therapeutic targets for breast cancer brain metastasis by understanding the role of inflammation and immune cells in the tumor microenvironment. Jennifer A. Kanakry, M.D. Jennifer A. Kanakry, M.D., has been appointed Senior Clinician and Director of the Hematology/Oncology Fellowship Program in CCR’s Office of the Clinical Director. She leads a clinical research program related to allogeneic hematopoietic cell transplantation for patients with hematologic malignancies and inherited and acquired disorders of the immune system. Alexander E. Kelly, Ph.D. Alexander E. Kelly, Ph.D., was awarded tenure at NIH and appointed as a Senior Investigator in the Laboratory of Biochemistry and Molecular Biology. His lab seeks to understand how errors in chromosome segregation are prevented and corrected using a combination of biochemical, biophysical and cell biological approaches. Mardo Kõivomägi, Ph.D. Mardo Kõivomägi, Ph.D., has joined the Laboratory of Biochemistry and Molecular Biology as a Stadtman Tenure-Track Investigator from Stanford University. Dr. Kõivomägi studies the biochemical mechanisms cyclin-dependent kinase complexes use to control cell division and how to target these mechanisms with novel therapeutics against cancer. Mikhail Kolmogorov, Ph.D. Mikhail Kolmogorov, Ph.D., has joined the Cancer Data Science Laboratory as a Stadtman Tenure-Track Investigator from the University of California, Santa Cruz. The focus of Dr. Kolmogorov’s lab research is computational genomics — algorithms, mathematical models and tools aimed at answering fundamental questions about living systems through the analysis of large-scale sequencing data. Vid Leko, M.D. Vid Leko, M.D., has joined the Immune Deficiency Cellular Therapy Program as a Physician-Scientist Early Investigator from the CCR Surgery Branch. Dr. Leko’s research focuses on developing T cell-based therapies for patients suffering from myelodysplastic syndromes, acute myeloid leukemia and other cancers resistant to current therapies.
RkJQdWJsaXNoZXIy Mzc5ODkz